Novo Nordisk reports positive pediatric obesity trial results

Novartis announced promising results from the third phase of its clinical study "STEP Young," which tests the efficacy and safety of once-weekly semaglutide treatment in children aged 6 to 12 years with severe obesity. The results showed a significant decrease in body mass index (BMI) after 68 weeks of treatment, with approximately 40.4% of children no longer classified as obese, compared to zero in the placebo group. The study confirms that semaglutide can help reduce weight in children with severe obesity, thereby decreasing the risk of future health complications such as heart disease and hypertension. It is considered a promising treatment for those who struggle with resistance to lifestyle changes.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل